Membranoproliferative glomerulonephritis screening: Difference between revisions
Nazia Fuad (talk | contribs) |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Membranoproliferative glomerulonephritis}} | |||
{{CMG}} ; {{AE}} {{JSS}} | |||
==Overview== | ==Overview== | ||
The entity, MPGN is a pathological definition, though it has some laboratory findings to guide to this diagnosis. Till now there is not specific screening protocols for MPGN, although it can diagnosed in the early stages by checking the proportion of urine protein to serum creatinine and 24 hour urine protein. | The entity, MPGN is a pathological definition, though it has some laboratory findings to guide to this diagnosis. Till now there is not specific screening protocols for MPGN, although it can diagnosed in the early stages by checking the proportion of urine protein to serum creatinine and 24 hour urine protein. | ||
Revision as of 17:06, 26 July 2018
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis screening On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis screening |
|
Membranoproliferative glomerulonephritis screening in the news |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
The entity, MPGN is a pathological definition, though it has some laboratory findings to guide to this diagnosis. Till now there is not specific screening protocols for MPGN, although it can diagnosed in the early stages by checking the proportion of urine protein to serum creatinine and 24 hour urine protein.